All In Biotech

Drug Trial Radar · NCT06237335

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

128

Actual

Start

Feb 1, 2024

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
ReCode TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Conditions

  • Cystic Fibrosis

Interventions

  • RCT2100Drug

    RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer

  • PlaceboOther

    Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer

  • RCT2100Drug

    RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks

  • RCT2100Drug

    RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks

  • IvacaftorDrug

    ivacaftor administered orally for 6 weeks

  • RCT2100Drug

    RCT2100 supplied at varying dose strengths. Co- administered via oral inhalation using nebulizer for 4 weeks with ivacaftor after initial 2 weeks of ivacaftor dosing run in period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).Time frame: From Baseline Through Day 29
  2. Part 2: The number of participants with CF with AEs and SAEs.Time frame: From Day 1 through Safety Follow-up, Week 24
  3. Part 3: The number of participants with CF with AEs and SAEs.Time frame: From Day 1 through Safety Follow-up, Week 24

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • Stanford University

    Palo Alto, California

  • UCSD

    San Diego, California

  • National Jewish Health

    Denver, Colorado

  • Emory University

    Atlanta, Georgia

  • Boston Children's Hospital

    Boston, Massachusetts

  • New York Medical College

    Valhalla, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Washington

    Seattle, Washington

  • Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve

    Montpellier, France

  • Hôpital Necker Enfants Malades

    Paris, France

  • UMC Utrecht

    Utrecht, Netherlands

  • New Zealand Clinical Research (Part 1 Only)

    Auckland, New Zealand

  • University Hospitals Birmingham

    Birmingham, United Kingdom

  • Royal Papworth Hospital

    Cambridge, United Kingdom

  • Leeds Teaching Hospitals

    Leeds, United Kingdom

  • King's College Hospital

    London, United Kingdom

  • Nottingham University Hospitals

    Nottingham, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.